PanOptica, Inc.

ACTIVE

新泽西州摩里斯县, New Jersey, United Stateswww.panopticapharma.comHolding101–250 employeesEstablished: 2009-01-01

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2009

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

100.0%

Trial Status Distribution

Active, not recruiting

57.1%

Completed

42.9%

Clinical Trials

Trials sponsored by this organization (7)

Safety and tolerability study to evaluate PAN-90806 for the treatment of neovascular Age-Related Macular Degeneration (AMD) in Treatment-naïve participants

Phase 1

Active, not recruiting

May 201860 participants

Safety and tolerability study to evaluate PAN-90806 for the treatment of neovascular Age-Related Macular Degeneration (AMD) in Treatment-naïve participants

Phase 1

Active, not recruiting

May 201860 participants

Safety and tolerability study to evaluate PAN-90806 for the treatment of neovascular Age-Related Macular Degeneration (AMD) in Treatment-naïve participants

Phase 1

Active, not recruiting

May 201860 participants

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

Phase 1

Completed

interventional

Apr 201851 participants

Safety and tolerability study to evaluate PAN-90806 for the treatment of neovascular Age-Related Macular Degeneration (AMD) in Treatment-naïve participants

Phase 1

Active, not recruiting

Apr 201851 participants

Study of Topical Ocular PAN-90806 in PDR

Phase 1

Completed

interventional

Aug 201510 participants

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

Phase 1

Completed

interventional

Feb 201450 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations